Bioinformatic analysis of the membrane cofactor protein CD46 and microRNA expression in hepatocellular carcinoma

Lu,Zejun; Zhang,Chuanfu; Cui,Jiajun; Song,Qi; Wang,Ligui; Kang,Jingbo; Li,Peng; Hu,Xiaofeng; Song,Hongbin; Yang,Jinliang; Sun,Yansong

doi:10.3892/or.2013.2877

Bioinformatic analysis of the membrane cofactor protein CD46 and microRNA expression in hepatocellular carcinoma

Authors:
- Zejun Lu
- Chuanfu Zhang
- Jiajun Cui
- Qi Song
- Ligui Wang
- Jingbo Kang
- Peng Li
- Xiaofeng Hu
- Hongbin Song
- Jinliang Yang
- Yansong Sun
View Affiliations

Affiliations: Institute of Disease Control and Prevention, Chinese Academy of Military Medical Sciences, Beijing 100071, P.R. China, Department of Gynaecology and Obstetrics, The General Hospital of the Chinese People's Armed Police Force, Beijing 100039, P.R. China, Department of Radiation Oncology, Naval General Hospital of PLA, Beijing 100048, P.R. China, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: November 28, 2013 https://doi.org/10.3892/or.2013.2877
Pages: 557-564
Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The therapeutic potential of membrane complement regulatory protein (mCRP)-neutralizing antibodies is unsatisfactory, which perhaps lies in the complex role of mCRPs in tumor occurrence and development. As a member of the mCRPs, CD46 is a transmembrane protein with a cytoplasmic domain and is implicated more in the control of the alternative complement pathway than of the classical complement pathway. Growing evidence has revealed that both the CD46 signaling pathway and microRNAs (miRNAs) play an important role in the development and progression of hepatocellular carcinoma (HCC). In the present study, we analyzed mCRP expression in different tumor tissues by employing western blotting and qPCR. To address the potential role of miRNAs in CD46 signaling, we set out to profile miRNA expression in CD46-overexpressed and -silenced HepG2 cell lines. Furthermore, bioinformatic analysis was performed to identify downstream targets of CD46 signaling. We found that the levels of CD46 expression in HCC tissues were significantly higher compared to that in the adjacent normal tissues. After complement-related gene expression profiling and unsupervised hierarchical clustering analysis of 10 HCC tissues, a total of 37 miRNAs showed significantly different expression levels before and after CD46 expression change. By bioinformatic analysis, we identified let-7b and miR-17 as downstream targets of CD46 signaling, and that the expression levels of let-7b and miR-17 were negatively correlated with that of CD46 in HepG2 cells. The present study suggests that CD46 plays an important role in HCC carcinogenesis by regulating let-7b and miR-17.

View Figures

View References

1	Duffy A and Greten T: Developing better treatments in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 4:551–560. 2010. View Article : Google Scholar : PubMed/NCBI
2	Lo CM, Ngan H, Tso WK, et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 35:1164–1171. 2002. View Article : Google Scholar : PubMed/NCBI
3	Holt DS, Botto M, Bygrave AE, Hanna SM, Walport MJ and Morgan BP: Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria. Blood. 98:442–449. 2001. View Article : Google Scholar : PubMed/NCBI
4	Halperin JA, Taratuska A and Nicholson-Weller A: Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells. J Clin Invest. 91:1974–1978. 1993. View Article : Google Scholar : PubMed/NCBI
5	Hadders MA, Bubeck D, Roversi P, et al: Assembly and regulation of the membrane attack complex based on structures of C5b6 and sC5b9. Cell Rep. 1:200–207. 2012. View Article : Google Scholar : PubMed/NCBI
6	Brodbeck WG, Mold C, Atkinson JP and Medof ME: Cooperation between decay-accelerating factor and in protecting cells from autologous complement attack. J Immunol. 165:3999–4006. 2000. View Article : Google Scholar : PubMed/NCBI
7	Kemper C, Chan AC, Green JM, Brett KA, Murphy KM and Atkinson JP: Activation of human CD4⁺cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature. 421:388–392. 2003.PubMed/NCBI
8	Matsumura N, Tagami H, Hotta T, Takemura S, Yoshikawa T and Kondo M: Serum complement profile and its clinical significance in patients with hepatocellular carcinoma and liver cirrhosis. Nihon Shokakibyo Gakkai Zasshi. 78:1753–1759. 1981.(In Japanese).
9	Baranyi L, Baranji K, Takizawa H, Okada N and Okada H: Cell-surface bound complement regulatory activity is necessary for the in vivo survival of KDH-8 rat hepatoma. Immunology. 82:522–528. 1994.PubMed/NCBI
10	Kinugasa N, Higashi T, Nouso K, et al: Expression of membrane cofactor protein (MCP, CD46) in human liver diseases. Br J Cancer. 80:1820–1825. 1999. View Article : Google Scholar : PubMed/NCBI
11	Spiller OB, Criado-García O, Rodríguez De Córdoba S and Morgan BP: Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack. Clin Exp Immunol. 121:234–241. 2000. View Article : Google Scholar : PubMed/NCBI
12	Law PT and Wong N: Emerging roles of microRNA in the intracellular signaling networks of hepatocellular carcinoma. J Gastroenterol Hepatol. 26:437–449. 2011. View Article : Google Scholar : PubMed/NCBI
13	Negrini M, Gramantieri L, Sabbioni S and Croce CM: microRNA involvement in hepatocellular carcinoma. Anticancer Agents Med Chem. 11:500–521. 2011. View Article : Google Scholar
14	Ladeiro Y, Couchy G, Balabaud C, et al: MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology. 47:1955–1963. 2008. View Article : Google Scholar : PubMed/NCBI
15	Ariizumi S, Katagiri S, Katsuragawa H, Kotera Y and Yamamoto M: Sectionectomy is suitable for patients with T2 hepatocellular carcinoma according to the modified International Union against Cancer TNM Classification. Dig Surg. 24:342–348. 2007. View Article : Google Scholar
16	Lu ZJ, Liu SY, Yao YQ, et al: The effect of miR-7 on behavior and global protein expression in glioma cell lines. Electrophoresis. 32:3612–3620. 2011. View Article : Google Scholar : PubMed/NCBI
17	Gao X, Gulari E and Zhou X: In situ synthesis of oligonucleotide microarrays. Biopolymers. 73:579–596. 2004. View Article : Google Scholar : PubMed/NCBI
18	Pan W: A comparative review of statistical methods for discovering differentially expressed genes in replicated microarray experiments. Bioinformatics. 18:546–554. 2002. View Article : Google Scholar
19	Treon SP, Mitsiades C, Mitsiades N, et al: Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother. 24:263–271. 2001. View Article : Google Scholar
20	Nakagawa M, Mizuno M, Kawada M, et al: Polymorphic expression of decay-accelerating factor in human colorectal cancer. J Gastroenterol Hepatol. 16:184–189. 2001. View Article : Google Scholar : PubMed/NCBI
21	Simpson KL, Jones A, Norman S and Holmes CH: Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal human uterine cervix and in premalignant and malignant cervical disease. Am J Pathol. 151:1455–1467. 1997.
22	Junnikkala S, Jokiranta TS, Friese MA, Jarva H, Zipfel PF and Meri S: Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1. J Immunol. 164:6075–6081. 2000. View Article : Google Scholar : PubMed/NCBI
23	Weichenthal M, Siemann U, Neuber K and Breitbart EW: Expression of complement regulatory proteins in primary and metastatic malignant melanoma. J Cutan Pathol. 26:217–221. 1999. View Article : Google Scholar : PubMed/NCBI
24	Kojima A, Iwata K, Seya T, et al: Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3-fragment deposition and cytolysis. J Immunol. 151:1519–1527. 1993.
25	Zell S, Geis N, Rutz R, Schultz S, Giese T and Kirschfink M: Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack. Clin Exp Immunol. 150:576–584. 2007. View Article : Google Scholar : PubMed/NCBI
26	Janssen EA, Slewa A, Gudlaugsson E, et al: Biologic profiling of lymph node negative breast cancers by means of microRNA expression. Mod Pathol. 23:1567–1576. 2010. View Article : Google Scholar : PubMed/NCBI
27	Herranz H and Cohen SM: MicroRNAs and gene regulatory networks: managing the impact of noise in biological systems. Genes Dev. 24:1339–1344. 2010. View Article : Google Scholar : PubMed/NCBI
28	Reinhart BJ, Slack FJ, Basson M, et al: The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 403:901–906. 2000. View Article : Google Scholar : PubMed/NCBI
29	Sempere LF, Christensen M, Silahtaroglu A, et al: Altered microRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res. 67:11612–11620. 2007. View Article : Google Scholar : PubMed/NCBI
30	Lan FF, Wang H, Chen YC, et al: Hsa-let-7g inhibits proliferation of hepatocellular carcinoma cells by downregulation of c-Myc and upregulation of p16^INK4A. Int J Cancer. 128:319–331. 2011. View Article : Google Scholar
31	Connolly E, Melegari M, Landgraf P, et al: Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol. 173:856–864. 2008. View Article : Google Scholar
32	Yang F, Yin Y, Wang F, et al: miR-17-5p promotes migration of human hepatocellular carcinoma cells through the p38 mitogen-activated protein kinase-heat shock protein 27 pathway. Hepatology. 51:1614–1623. 2010. View Article : Google Scholar : PubMed/NCBI
33	Zheng J, Dong P, Gao S, Wang N and Yu F: High expression of serum miR-17-5p associated with poor prognosis in patients with hepatocellular carcinoma. Hepatogastroenterology. 60:549–552. 2012.PubMed/NCBI
34	Chen L, Jiang M, Yuan W and Tang H: miR-17-5p as a novel prognostic marker for hepatocellular carcinoma. J Invest Surg. 25:156–161. 2012. View Article : Google Scholar : PubMed/NCBI